Name: Compounded NAD+ Injection
Brand: Peptide12
Rating: 5 (6 reviews)

Question 1

What is NAD+ and why does it decline with age?

Accepted Answer

NAD+ is a coenzyme present in every cell, central to mitochondrial ATP production and the obligate substrate for sirtuin and PARP enzymes that maintain DNA and regulate longevity signaling. Tissue NAD+ falls roughly 50% by age 60.

By restoring NAD+ substrate directly via subcutaneous injection, this protocol may support steadier daily energy, mental clarity, and the cellular repair machinery the body relies on with age. A balanced, science-based approach to longevity.

Question 2

How is subcutaneous injection different from IV NAD+?

Accepted Answer

IV NAD+ delivers a large dose (typically 250–1000 mg) over a multi-hour clinic infusion. Subcutaneous injection delivers smaller doses (50–200 mg) at home, 2–3 times per week. SC absorption is slower and gentler — flushing and nausea are usually milder than IV — and the cumulative weekly delivery is comparable. SC is the standard telehealth route because it removes the chair time, the IV access, and the cost of clinic infusions, while still raising tissue NAD+ levels through consistent dosing.

Question 3

When will I notice the effects?

Accepted Answer

Energy and mental-clarity changes are typically reported within 1–3 weeks of consistent dosing. Sleep and recovery improvements often follow at 3–6 weeks. The longer-term cellular benefits — sirtuin and DNA-repair effects — are not subjectively felt and are inferred from mechanism. Individual response varies based on baseline NAD+ status, age, sleep quality, and overall metabolic health.

Question 4

Can I take NAD+ injections with NMN or NR oral precursors?

Accepted Answer

Some patients combine injectable NAD+ with oral precursors like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside), which the body converts into NAD+. The injection delivers NAD+ directly to the bloodstream; oral precursors raise the supply pool more gradually. There is no major interaction concern, but doubling up rarely doubles the effect and may not be cost-effective. Discuss any stack with your prescribing doctor before adding oral precursors.

Question 5

Is NAD+ safe long-term?

Accepted Answer

NAD+ has been used clinically for decades, originally in addiction-recovery infusions, and has a generally favorable safety profile at standard subcutaneous doses. The most common considerations are flushing, nausea, and injection-site reactions, which usually resolve with slower injection and titration. The most important contraindication is active or recent malignancy, since NAD+ is required for cell proliferation as well as repair. Routine 8-on / 2-off cycling is common to allow reassessment and limit habituation.

Question 6

What is the difference between NAD+ injection, nasal spray, and face cream?

Accepted Answer

NAD+ injection is the highest-bioavailability route — the coenzyme reaches systemic circulation directly. NAD+ nasal spray offers needle-free dosing with faster onset than oral routes and bypasses first-pass metabolism, but at lower systemic levels per dose. NAD+ face cream is topical and targeted to skin-cell metabolism rather than systemic NAD+ status. They serve different goals: injection for systemic cellular energy, nasal spray for convenient daily maintenance, face cream for skin-specific use.

Question 7

Should I do an IV loading dose first?

Accepted Answer

There is no consistent evidence that an IV loading dose improves long-term outcomes versus starting subcutaneous and titrating up. Some patients choose a clinic IV for the experience or for a faster initial subjective response, but it is not required and adds significant cost. Starting low subcutaneously and titrating is the standard telehealth approach and is what your prescribing doctor will typically recommend.

Question 8

How does Peptide12 source NAD+?

Accepted Answer

Peptide12 partners with FDA-registered 503A compounding pharmacies that hold state and federal licensure and undergo regular USP <797> sterility audits. Every batch is third-party tested for identity, potency, sterility, and endotoxin before release. Compounded NAD+ is not FDA-approved as a finished drug product but is prepared from FDA-regulated active pharmaceutical ingredient under individualized prescription.